BioMed Research International

BioMed Research International / 2021 / Article

Review Article | Open Access

Volume 2021 |Article ID 5543185 | https://doi.org/10.1155/2021/5543185

Wen-Ying Yu, Chun-Xiao Gao, Huan-Huan Zhang, Yue-Guo Wu, Chen-Huan Yu, "Herbal Active Ingredients: Potential for the Prevention and Treatment of Acute Lung Injury", BioMed Research International, vol. 2021, Article ID 5543185, 19 pages, 2021. https://doi.org/10.1155/2021/5543185

Herbal Active Ingredients: Potential for the Prevention and Treatment of Acute Lung Injury

Academic Editor: Paul Vernyuy Tan
Received09 Feb 2021
Accepted15 Jun 2021
Published23 Jun 2021

Abstract

Acute lung injury (ALI) is a life-threatening clinical syndrome with high morbidity and mortality. The main pathological features of ALI are increased alveolar-capillary membrane permeability, edema, uncontrolled migration of neutrophils to the lungs, and diffuse alveolar damage, resulting in acute hypoxemic respiratory failure. Glucocorticoids, aspirin, and other anti-inflammatory drugs are commonly used to treat ALI. Respiratory supports, such as a ventilator, are used to alleviate hypoxemia. Many treatment methods are available, but they cannot significantly ameliorate the quality of life of patients with ALI and reduce mortality rates. Herbal active ingredients, such as flavonoids, terpenoids, saponins, alkaloids, and quinonoids, exhibit advantages for ALI prevention and treatment, but the underlying mechanism needs further study. This paper summarizes the role of herbal active ingredients in anti-ALI therapy and progresses in the understanding of their mechanisms. The work also provides some references and insights for the discovery and development of novel drugs for ALI prevention and treatment.

1. Introduction

Acute lung injury (ALI) is a common clinical syndrome with high morbidity and mortality and is caused by various pathological and structural changes due to direct and indirect injury factors in lung tissues. The pathological feature of this disease is damage to alveolar epithelial and microvascular endothelial cells. The former can cause edema in the alveolar cavity, exudation of fibrin and collagen, and aggregation of neutrophils, eventually leading to lung consolidation. The latter increases vascular permeability, which causes the aggregation of inflammatory cells and leads to pulmonary vascular congestion and pulmonary interstitial edema [1]. Therefore, the main factor in ALI development is the imbalance in inflammatory response, which damages diffuse alveolar and pulmonary vascular endothelial cells and may lead to oxidation/reduction imbalance [2].

The international treatment for ALI mainly includes reduction in inflammation damage and suppression of respiratory failure. Anti-inflammatory drugs, such as glucocorticoids and aspirin, are commonly used in clinics. Respiratory support, such as ventilators, is employed to relieve hypoxemia. Although many treatments are available, the patient’s quality of life remains poor, and mortality is not reduced [3]. The activities of active ingredients from herbs in preventing and treating ALI have been recently explored. These substances show a broad application prospect. However, despite their widespread existence and recognized biological activities, no integral review of their mechanisms of action for ALI has been undertaken. This review is aimed at integrating and discussing the most promising anti-ALI compounds isolated from herbs over the last 10 years (2011-2020). For the collection of relevant information, reviews and single publications were searched on PubMed, SciFinder, ScienceDirect, and similar databases with relevant keywords, such as flavonoids, terpenoids, saponins, alkaloids, quinonoids, phenols, organic acids, coumarins, lignans, and ALI. Only in vivo research articles have been selected, and the mechanisms of action have been discussed. This work provides important clues and direction for the discovery of anti-ALI drugs.

2. Potential Effects of Herbal Active Ingredients on Experimental ALI

2.1. Flavonoids

Flavonoids constitute a group of compounds with 2-phenyl chromone structures; they are widely present in natural plants and have a variety of biological activities, such as antioxidant, anti-inflammatory, anticancer, antibacterial, and antiviral activities [4]. Their anti-inflammatory and antioxidant activities render them useful preventive and therapeutic candidates for inflammatory lung diseases.

Naringin is a natural 2,3-dihydro-flavonoid derived from Exocarpium Citri Grandis. Chen et al. [5] found that naringin can protect paraquat- (PQ-) induced ALI by downregulating the levels of transforming growth factor-β1 (TGF-β1), tumor necrosis factor-α (TNF-α), tissue inhibitor of metalloproteinase-1 (TIMP-1), and matrix metalloprotein-9 (MMP-9) and increasing the activities of glutathione peroxidase (GSH-Px), superoxide dismutase (SOD), and heme oxygenase-1 (HO-1). The compound exhibits mucoactive effects in lipopolysaccharide- (LPS-) induced ALI in mice and beagle dogs by reducing goblet cell hyperplasia and excessive mucus secretion and promoting sputum excretion [6].

Tectorigenin, an isoflavone aglycone, is obtained from Belamcanda chinensis. Tectorigenin treatment can attenuate inflammatory cell number in bronchoalveolar lavage fluids (BALF), reduce the mRNA and protein expression levels of nuclear factor kappa b (NF-κB) p65 in the lungs, improve SOD activity, and inhibit myeloperoxidase (MPO) activity. It exhibits a protective effect on LPS-mediated ALI in mice [7].

Baicalin is a flavonoid glycoside isolated from Scutellaria baicalensis and can alleviate ALI induced by various factors. Meng et al. [8] found that it can provide protection against LPS-induced severe lung injury in mice by activating the nuclear factor E2-related factor 2- (Nrf2-) mediated HO-1 signaling pathway, which suppresses inflammation and oxidative stress. Baicalin can ameliorate severe burn-induced remote ALI in rats by suppressing the Nod-like receptor pyrin domain-containing protein 3 (NLRP3) signaling pathway [9] and avian pathogenic Escherichia coli- (E. coli-) induced ALI in chicken by restraining the activation of the NF-κB pathway [10].

Hesperidin is a flavanone glycoside, which is found mainly in citrus fruit peel. In sepsis-induced ALI models, treatment with hesperidin can provide protection against lung injury by attenuating the levels of B-cell lymphoma-2 (Bcl-2), caspase-3, heat shock protein 70 (Hsp70), toll-like receptor 4 (TLR4), and myeloid differential protein-88 (MyD88) in the lung tissues [11]. In an H1N1-induced ALI model, hesperidin exhibits efficacy in alleviating pulmonary inflammation and impairment by suppressing cytokine production through mitogen-activated protein kinase (MAPK) pathways in pulmonary microvascular endothelial cells [12]. In an LPS-induced ALI model, hesperidin pretreatment can modulate lung injury by inhibiting the infiltration of macrophages and suppressing the release of high-mobility group box-1 protein (HMGB1) [13].

Apigenin (4,5,7-trihydroxyflavone) is a natural flavonoid compound and abundantly present in common fruits and vegetables, such as celery, apple, and onion. It can reverse ALI and immunotoxicity in PQ-induced mice by increasing GSH-Px, catalase (CAT), and SOD activities and decreasing the levels of proinflammatory cytokines and malondialdehyde (MDA) [14]. Apigenin pretreatment can protect LPS-induced ALI in mice, and the protective mechanism of apigenin might be partially due to the inhibited activation of cyclo-oxygen-ase-2 (COX-2) and NF-κB and subsequent decreased production of proinflammatory mediators [15]. Table 1 lists the potential effects of flavonoids on ALI. The structure of representative flavonoids is shown in Figure 1. In general, the key structural features of active flavonoids are unsaturation in the C ring (Δ2), the number and position of OH groups at the A and B rings, the carbonyl group at C-4 at ring C, and frequently, nonglycosylation of the molecules [16]. When these features are considered, one may infer that natural products, such as flavonoids, are useful in developing novel substances for ALI treatment.


Active ingredientsModels of ALIDoses (mg/kg)Relevant findingsRef.

NaringinALI in mice induced by PQ60 and 120Reduce the levels of TNF-α, TGF-β1, TIMP-1, and MMP-9[5]
ALI in mice induced by LPS
ALI in dogs induced by LPS
15 and 60 12.4Reduce airway mucus secretion and goblet cell hyperplasia, promote sputum excretion[6]
TectorigeninALI in mice induced by LPS5 and 10Decrease the expression of NF-κB p65 at both mRNA and protein levels, improve SOD activity, and inhibit MPO activity[7]
BaicalinALI in mice induced by LPS200Activate Nrf2/HO-1 pathway[8]
ALI in rats induced by severe burn80Modulate NLRP3 inflammasome pathways[9]
ALI in chicken induced by APEC50, 100, and 200Inhibit NF-κB pathway[10]
HesperidinALI in mice induced by CLP10 and 20Induce the Hsp70/TLR4/MyD88 pathway[11]
ALI in mice induced by H1N150, 200, and 500Reduce proinflammatory cytokine production by inhibiting MAPK pathways[12]
ALI in mice induced by LPS500Suppress HMGB1 expression and release[13]
ApigeninALI in mice induced by PQ20 and 50Increase the level of MDA and decrease the activity of antioxidase[14]
ALI in mice induced by LPS10 and 20Inhibit the activation of COX-2 and NF-κB[15]
RutinALI in mice induced by LPS0.61, 6.1, and 61Suppress the expressions of VCAM-1 and iNOS[101]
TroxerutinALI in mice induced by LPS150Inhibit MAPK and NF-κB pathways[102]
Hydroxysafflor yellow AALI in rats induced by OA15Activate cAMP/PKA pathway[103]
ALI in mice induced by LPS40, 80, and 120Inhibit TLR4-dependent pathways[92]
ALI in mice induced by BLM26.7, 40, and 60Inhibit NF-κB activation and p38 MAPK phosphorylation[94]
EGCGALI in mice induced by LPS10Suppress TLR4/NF-κB pathway[104]
ALI in mice induced by PQ5, 10, and 20Inhibit TLR/NF-κB pathway[105]
ALI in mice induced by H9N210Inhibit TLR4/NF-κB pathway[106]
KaempferolALI in mice induced by LPS50Modulate TRAF6 polyubiquitination[107]
ALI in mice induced by CLP100Suppress oxidative stress, iNOS, and ICAM-1 pathways[108]
ALI in mice induced by H9N215Inhibit TLR4/MyD88/NF-κB and MAPK pathways[109]
LuteolinALI in mice induced by LPS1 and 10Inhibit the activity of iNOS/NO, COX-2, HMGB1, and NF-κB[110]
ALI in mice induced by HgCl2100Prevent NF-κB activation and activate AKT/Nrf2 pathway[111]
QuercetinALI in mice induced by LPS25 and 50Activate cAMP-Epac pathway[112]
ALI in rats induced by CLP30 and 50Inhibit ICAM-1 and MIP-2 expression[113]
ALI in mice induced by seawater instillation200Inhibit macrophage M1 polarization and proinflammatory cytokine expression[114]
DihydromyricetinALI in mice induced by CLP50, 100, and 150Inhibit NLRP3 inflammasome-dependent pyroptosis[115]
IsoliquiritigeninALI in mice induced by LPS30Activate AMPK/Nrf2/ARE signaling and inhibit NF-κB and NLRP3 activation[116]

2.2. Terpenoids

Terpenoids are compounds with the general formula of (C5H8)n, and their oxygenated derivatives and derivatives with different degrees of saturation can be considered natural compounds linked by isoprene or isopentane in various ways. Some terpenoids have antibacterial, antioxidant, tumor suppression, hepatoprotective, anti-inflammatory, and other biological activities [17, 18].

Andrographolide is a diterpenoid lactone extracted from Andrographis paniculata and commonly used to treat respiratory infection. Peng et al. [19] found that andrographolide can ameliorate ovalbumin- (OVA-) induced ALI in mice by inhibiting the reactive oxygen species- (ROS-) mediated activation of the NF-κB and NLRP3 inflammasome signaling pathway. In addition, andrographolide contributes to the amelioration of lung inflammation and fibrosis induced by radiation and can suppress absent in melanoma 2 (AIM2) from translocating to the nucleus to sense DNA damage caused by chemotherapeutic agents or radiation in bone marrow-derived macrophages [20]. It exhibits antioxidative properties and can provide protection against cigarette smoke- (CS-) induced ALI by increasing Nrf2 activity [21].

Oridonin, isolated from Rabdosia rubescens, is an ent-kaurene diterpenoid that possesses antioxidative and anti-inflammatory effects. It can provide protection against LPS-mediated ALI by regulating Nrf2-dependent oxidative stress and Nrf2-independent NF-κB and NLRP3 pathways [22] and alleviate hyperoxia-induced lung injury. Treatment with 10 mg/kg oridonin can attenuate lung pathology, reduce lung edema, decrease TNF-α and MDA levels, and increase interleukin- (IL-) 10 and GSH levels in the lungs of model mice [23].

Betulin and betulinic acid are natural pentacyclic triterpenoids derived from various plants, including white birch bark. Zhao et al. [24] found that betulin can reduce lung damage caused by cecal ligation and puncture (CLP) and improve the survival rates of rats. This protective effect may be mediated by its anti-inflammatory effect and NF-κB and MAPK inhibition. Betulinic acid pretreatment can decrease the levels of oxidants and increase the levels of antioxidants in plasma and lungs, thereby reducing oxidative lung damage in CLP mice [25].

Asiatic acid is a pentacyclic triterpene derived from Centellae asiaticae herba. It can ameliorate LPS-induced histopathological changes in the lungs of mice by suppressing the production of inflammatory cytokines, and process is mediated by the blocked activation of TLR4-mediated NF-κB signaling [26]. Asiatic acid exerts a considerable protective effect on spinal cord injury- (SCI-) induced ALI by blocking NLRP3 inflammasome activation and oxidative stress and by upregulating Nrf2 expression [26]. The potential effects of terpenoids from herbs on ALI are shown in Table 2. The structures of representative terpenoids are shown in Figure 2. Structure-activity analysis shows that the introduction of acyl groups into the mother nuclei of terpenoids improves the anti-inflammatory activity of terpenoids, and increasing the amount of acyl groups and lengths of acyl carbon chains enhances this effect. The type of substituents on the C rings of polycyclic terpenoids is the main reason for their anti-inflammatory activity, and rosin/pimonane diterpenoids and ingenane diterpenoids have good inhibitory activities against NO production [27].


Active ingredientsModels of ALIDoses (mg/kg)Relevant findingsRef.

AndrographolideALI in mice induced by OVA5 and 10Suppress ROS-mediated NF-κB signaling and NLRP3 inflammasome activation[19]
ALI in mice induced by radiation5, 10, and 20Suppress AIM2 inflammasome-mediated pyroptosis in macrophage[20]
ALI in mice induced by CS0.1, 0.5, and 1Augment the activity of Nrf2[21]
OridoninALI in mice induced by LPS20 and 40Exert protective effects through Nrf2-independent anti-inflammatory and Nrf2-dependent antioxidative activities[22]
ALI in mice induced by hyperoxia10Reduce MDA and TNF-α, and increase GSH and IL-10 in the lungs[23]
BetulinALI in rats induced by CLP4 and 8Inhibit NF-κB and MAPK pathway[24]
Betulinic acidALI in mice induced by CLP3, 10, and 30Decrease the levels of oxidants, increase the levels of antioxidants in the lungs and plasma[25]
Asiatic acidALI in mice induced by LPS25, 50, and 100Block the TLR4/NF-κB pathway[26]
ALI in rat induced by SCI30 and 75Inhibit NLRP3 inflammasome activation and oxidative stress with the upregulation of Nrf2[117]
Acanthoic acidALI in mice induced by LPS15, 30, and 60Upregulate the expression of LXRα[100]
PaclitaxelALI in mice induced by CLP0.075, 0.150, 0.225, and 0.300Activate MUC1 and suppress TLR4/NF-κB pathway[118]
GeraniolALI in mice induced by LPS12.5, 25, and 50Inhibit TLR4-mediated NF-κB and Bcl-2/Bax pathways[119]
TriptolideALI in mice induced by LPS0.005, 0.010, and 0.015Activate PPAR-γ[97]
CitralALI in mice induced by LPS10, 20, and 40Activate PPAR-γ[98]
GeniposideALI in mice induced by LPS20, 40, and 80Block NF- κB and MAPK pathway[120]
Jolkinolide BALI in mice induced by LPS2 and 10Suppress the activation of NF-κB and MAPK[121]
TaraxasterolALI in mice induced by LPS2.5, 5, and 10Inhibit the NF-κB and MAPK pathways[122]

2.3. Saponins

Saponins are glycosides composed of triterpene or spiral sterane and mainly distributed in terrestrial higher plants. Saponins have multiple biological activities, such as anti-inflammatory, antibacterial, and antiviral activities, and may prevent or treat ALI [28].

Asiaticoside, a triterpenoid saponin derived from Centella asiatica, possesses potential anti-inflammatory and antioxidant activities. Qiu et al. [29] found that asiaticoside can attenuate LPS-induced ALI in a dose-dependent manner by inhibiting NF-κB p65 subunit phosphorylation and IκBα degradation. Asiaticoside can provide protection against CLP-induced ALI, and its underlying mechanisms may be related to the activation of peroxisome proliferator-activated receptor-γ (PPAR-γ) to some extent, which suppresses MAPKs and the NF-κB signaling pathway [30].

Platycodin D is the main triterpene saponin extracted from the Chinese herb Platycodonis radix and has anti-inflammatory and immunomodulatory activities. The anti-inflammatory effects of platycodin D may be associated with the activation of the liver x receptor α (LXRα)/ATP-binding cassette transporter A1 (ABCA1) signaling pathway, which disrupts the formation of lipid rafts by depleting cholesterol and preventing the translocation of TLR4 to lipid rafts, thereby blocking LPS-induced ALI [31]. Tao et al. [32] found that platycodin D pretreatment or posttreatment can improve ALI induced by LPS or BLM. Platycodin D can suppress apoptosis and inflammation by downregulating the levels of caspase-3, Bcl2-associated X protein (Bax), and NF-κB and upregulating the level of Bcl-2 in lung tissues and improve the SOD activity in BALF.

Dioscin, a natural steroid saponin mainly derived from Dioscorea villosa, can serve as an anti-inflammatory agent. Treatment with dioscin can attenuate oxidative stress, lung inflammatory response, and ALI in BLM-challenged mice [31]. Furthermore, dioscin can also alleviate LPS-induced ALI by inhibiting TLR4 signaling pathways [33].

Ginsenosides form a class of steroid glycosides and triterpene saponins. As the main active ingredients in Ginseng radix, they have various pharmacological effects, such as immunity enhancement and antiageing and antitumor effects [3436]. Ginsenosides include Rb1, Rg1, Rg3, GRh2, and other monomeric saponins. The ginsenoside Rb1 can provide protection against Staphylococcus aureus- (S. aureus-) induced ALI in mice. It can inhibit TNF-α, IL-1β, and IL-6 production and TLR2 activation. Furthermore, Rb1 effectively downregulates the phosphorylation of extracellular regulated kinases (ERK), p65, and c-Jun N-terminal kinase (JNK). These results demonstrated that Rb1 can alleviate lung injury by inhibiting TLR2-mediated NF-κB and MAPK pathways [37]. Rg1 can relieve sepsis-induced ALI by upregulating SIRT1 to relieve endoplasmic reticulum (ER) stress and inflammation [38], and ginsenoside Rg1 pretreatment can attenuate ALI induced by hind limb ischemia-reperfusion (IR) by inhibiting the NF-κB/COX-2 signaling pathway [39]. Rg3 treatment can mitigate LPS-induced pathological damage in the lungs by increasing the production of anti-inflammatory mediators and reducing the levels of proinflammatory cytokines. This process is mediated by MerTK-dependent activation of its downstream PI3K/AKT/mTOR pathway. These findings identified a new site of the specific anti-inflammatory mechanism of ginsenoside Rg3 [40]. Rg3 exhibits a protective effect against omethoate-induced ALI in rats, and the mechanisms may be related to its antioxidant potential and anti-inflammatory effects [41]. The anti-inflammatory effect of Rh2 has made it one of the most important ginsenosides. Hsieh et al. [42] found that Rh2 can ameliorate LPS-induced lung injury by blocking the TLR4/PI3K/Akt/mTOR, Raf-1/MEK/ERK, and Keap1/Nrf2/HO-1 signaling pathways in mice.

Glycyrrhizin is an extractive component isolated from Glycyrrhiza glabra L. roots and has various pharmacological effects. It exerts protective effects in various ALI models. In a radiation-induced ALI model, glycyrrhizin mitigated radiation-induced ALI by suppressing the HMGB1/TLR4 pathway [43]. In a LPS-induced ALI model, glycyrrhizin exerted anti-inflammatory effects by suppressing TLR4/NF-κB signaling [44]. In a Streptococcus aureus-induced ALI model, glycyrrhizin mitigated lung inflammation after Streptococcus aureus infection by inhibiting NF-κB, p38/ERK pathways, and pyroptosis [45]. Table 3 shows the potential effects of saponins from herbs on ALI. The structures of representative saponins are shown in Figure 3. By summarizing the structure-activity relationship of saponins, the anti-inflammatory activities of the compounds were found to be closely related to the types of substituted sugar groups and to increase with the number of substituted sugar groups. In addition, the positions and number of hydroxyl groups on the mother nucleus have a strong influence on the anti-inflammatory activities of saponins [46].


Active ingredientsModels of ALIDoses (mg/kg)Relevant findingsRef.

AsiaticosideALI in mice induced by LPS15, 30, and 45Inhibit NF-κB pathway[29]
ALI in mice induced by CLP45Upregulate PPAR-γ expression, inhibit MAPK and NF-κB pathway[30]
Platycodin DALI in mice induced by LPS20, 40, and 80Activate LXRα-ABCA1 pathway[31]
ALI in mice induced by LPS or BLM50 and 100Suppress apoptosis and inflammation[32]
DioscinALI in mice induced by BLM80Attenuate oxidative stress and the inflammatory response[123]
ALI in mice induced by LPS20, 40, and 80Inhibit NF-κB activation as well as TLR4 expression[33]
Ginsenoside Rb1ALI in mice induced by S. aureus10 and 20Attenuate NF-κB and MAPK activation[37]
Ginsenoside Rg1ALI in mice induced by CLP10 and 20Upregulate SIRT1 to relieve ER stress and inflammation[38]
ALI in rats induced by IR40Regulate NF-κB/COX-2 pathway[39]
Ginsenoside Rg3ALI in mice induced by LPS10, 20, and 30Activate MerTK-dependent PI3K/AKT/mTOR pathway[40]
ALI in rats induced by omethoate5, 10, and 20Reduce inflammation and oxidation[41]
Ginsenoside Rh2ALI in mice induced by LPS5, 10, and 20Regulate the TLR4/PI3K/Akt/mTOR, Raf-1/MEK/ERK, and Keap1/Nrf2/HO-1 pathways[42]
GlycyrrhizinALI in mice induced by radiation10Inhibit the HMGB1/TLR4 pathway[43]
ALI in mice induced by LPS50Inhibit the TLR4/NF-κB pathway[44]
ALI in mice induced by S. aureus25Inhibit NF-κB, p38/ERK pathways, and pyroptosis[45]
Astragaloside IVALI in rats induced by CLP2.5, 5, and 10Improve pulmonary ventilation, decrease alveolar-capillary permeability[88]
ALI in mice induced by PQ50 and 100Suppress Rho/ROCK/NF-κB pathway[124]
Saikosaponin AALI in mice induced by LPS5, 10, and 20Inhibit NF-κB and NLRP3 pathways[125]
TenuigeninALI in mice induced by LPS2, 4, and 8Inhibit NF-κB and MAPK pathways[126]
Esculentoside AALI in mice induced by LPS15, 30, and 60Inhibit NF-κB and MAPK pathways[127]

2.4. Alkaloids

Alkaloids are nitrogen-containing organic compounds that exist widely in nature. Most alkaloids have special and significant physiological activities, such as anti-inflammatory, antiviral, antitumor, and immune regulation activities [47, 48].

Berberine, an isoquinoline alkaloid, is extracted from Coptis chinensis and other Berberis plants. It can reduce lung histopathological changes through the protein kinase R-like endoplasmic reticulum kinase-mediated Nrf2/HO-1 signaling axis [49]. Berberine pretreatment can diminish CS-mediated lung inflammation by inhibiting the secretion of proinflammatory factors and NF-κB activity [50].

Sinomenine is an isoquinoline alkaloid extracted from Sinomenium acutum. It can provide protection against E. coli-induced ALI in mice by activating Nrf2 and inhibiting NF-κB pathways [51] and can effectively attenuate severe septic-associated ALI possibly by suppressing inflammation and oxidative damage through the activation of autophagy and Nrf2 signaling [52].

Matrine is the main active ingredient of Sophora flavescens. Liou et al. [53] found that it can prevent ALI in LPS-induced mice by decreasing the expression levels of COX-2, intercellular cell adhesion molecule-1 (ICAM-1), TNF-α, and IL-6.

Protostemonine is an active alkaloid mainly extracted from Stemona sessilifolia. In mice treated with protostemonine, heat-killed methicillin-resistant S. aureus- (HKMRSA-) mediated ALI can be alleviated through the suppression of the MAPK and NF-κB pathways [54]. Protostemonine can also effectively ameliorate LPS-induced lung inflammatory responses; the beneficial effects may be related to the downregulation of MAPK and AKT phosphorylation and reduction in the expression levels of proinflammatory mediators (such as NO, iNOS, and cytokines) [55].

Betanin is a quaternary ammonium alkaloid, mainly present in red beet roots. Treatment with betanin can protect rats from PQ-induced ALI interstitial pneumonia. The mechanisms may be associated with the increased levels of zonula occluden-1 and claudin-4, decreased levels of TNF-α and IL-1, and inhibited NF-κB activity [56]. Table 4 shows the potential effects of alkaloids from herbs on ALI. The structures of representative alkaloids are shown in Figure 4. The structural factors affecting the antioxidant activity of alkaloids are mainly stereostructure and electrical effects. The “exposure” of the nitrogen atoms in the heterocyclic ring facilitates reactions with ROS, resulting in antioxidant effects. Electron-donating groups in alkaloids or structural factors that can enrich nitrogen atoms with electrons can increase antioxidant activity [57]. Borcsa et al. [58] found that the chain length and unsaturation of the C-8 ester groups of aconitine derivatives play important roles in the anti-inflammatory activity. The toxicity of its derivative with a substituted long-chain ester group at the C-8 position is reduced relative to that of aconitine.


Active ingredientsModels of ALIDoses (mg/kg)Relevant findingsRef.

BerberineALI in mice induced by LPS10Activate PERK-mediated Nrf2/HO-1 signaling axis[49]
ALI in mice induced by CS50Inhibit NF-κB activation[50]
SinomenineALI in mice induced by E. coli100Inhibit the activation of NF-κB and upregulate the expression of Nrf2[51]
ALI in mice induced by LPS100Activate Nrf2 and autophagy[52]
MatrineALI in mice induced by LPS10 and 20Decrease the expressions of COX-2 and ICAM-1[53]
ProtostemonineALI in mice induced by HKMRSA20Inhibit MAPK and NF-κB pathways[54]
ALI in mice induced by LPS10Inhibit iNOS and NO expression, and suppress MAPK and PI3K/AKT signaling transduction in macrophages[55]
BetaninALI in rats induced by PQ25 and 100Decrease the levels of IL-1 and TNF-α, and the activity of NF-κB[56]
TabersonineALI in mice induced by LPS20 and 40Reduce the K63-linked polyubiquitination of TRAF6[128]
AnisodamineALI in rats induced by LPS10Inhibit the levels of IL-17A and IL-17F[129]
MagnoflorineALI in mice induced by LPS5, 10, and 20Suppress TLR4-mediated NF-κB and MAPK activation[130]
SophocarpineALI in mice induced by LPS12.5, 25, and 50Inhibit TLR4-mediated NF-κB and MAPK pathways[131]

2.5. Quinonoids

Quinonoids form a large class of natural bioactive molecules with unsaturated cyclodiketone structures (quinone structures) and are mainly divided into four types: benzoquinones, phenanthrenequinones, naphthoquinones, and anthraquinones. Quinonoids exhibit multiple pharmacological activities, such as antibacterial, anti-inflammatory, antiviral, and anticancer effects, and especially play a crucial role in ALI prevention and treatment [59, 60].

Emodin is an anthraquinone derivative isolated from rhubarb and has protective effects in various lung injury models. Dong et al. [61] found that emodin can reactivate autophagy and alleviate inflammatory lung injury in mice with lethal endotoxemia. Another study showed that emodin might provide protection against severe acute pancreatitis- (SAP-) associated ALI by reducing the expression of pre-B-cell colony-enhancing factor and enhancing neutrophil apoptosis through mitochondrial and death receptor apoptotic pathways [62]. Meanwhile, emodin exhibits protective effects on CLP-induced ALI in rats, and the molecular mechanism may be associated with the suppression of p38 MAPK signaling and reduction in oxidative damage and inflammation responses [63]. Moreover, emodin can also attenuate CS-mediated oxidative damage and lung inflammation in mouse models by inhibiting ROS production [64].

Chrysophanol is one of the main active ingredients of rhubarb. Treatment with chrysophanol can attenuate PQ-induced lung inflammation by increasing PPAR-γ expression and blocking the NF-κB pathway [65].

Tanshinone IIA is a derivative of phenanthrenequinone isolated from the root of Salvia miltiorrhiza. It can prevent LPS-induced expression and proinflammatory mediator secretion, thus exerting a protective effect against ALI probably through the regulation of the Sirt1/NF-κB pathway [66]. Wang et al. [67] investigated the effect and mechanism of tanshinone IIA on PQ-induced ALI. The results indicated that tanshinone IIA exerted a therapeutic effect on ALI rats by decreasing the levels of Ang-(1-7) and angiotensin-converting enzyme 2 (ACE2) in the lungs. Tanshinone IIA also exerts a marked protective effect on seawater aspiration-mediated ALI partly through the downregulation of macrophage migration inhibitory factor and NF-κB activity and TNF-α and IL-6 expression [68].

Cryptotanshinone is one of the major active compounds of Salvia miltiorrhiza. Cryptotanshinone pretreatment can significantly inhibit LPS-induced neutrophil infiltration in lung tissues. The anti-inflammatory effects of cryptotanshinone may be due to its ability to suppress TLR4-mediated NF-κB signaling [69]. Moreover, cryptotanshinone treatment can ameliorate radiation-induced ALI by suppressing the production and secretion of inflammatory cytokines and inhibiting the activation of CC chemokine ligand 3 (CCL3)/CC chemokine receptor 1 (CCR1) [70].

Embelin is a naturally occurring hydroxybenzoquinone mainly obtained from Embelia ribes. Embelin treatment can efficiently relieve PQ-incited lung damage, and the mechanism may be related to the inhibition of oxidative stress, inflammation cascade, and MAPK/NF-κB signaling pathway [71].

Shikonin is a naphthoquinone isolated from Lithospermum. Treatment with shikonin can improve sepsis-induced ALI by increasing miRNA-140-5p expression, depressing TLR4 expression, and suppressing the expression of downstream MyD88 and NF-κB [72]. Myeloid differentiation protein 2 (MD2) plays a key role in mediating inflammation. Zhang et al. [73] found that shikonin can inhibit the formation of the MD2-TLR4 complex in an ALI mouse model, thereby reducing LPS-mediated inflammation. Table 5 shows the potential effects of quinonoids from herbs on ALI. The structures of representative quinonoids are shown in Figure 5. Structure-activity relationship analysis showed that the number and locations of OH groups on the benzene rings of quinonoids seem to be largely responsible for the observed large variations in the trends of antioxidative and anti-inflammatory properties. Nam et al. [74] found that compared with quinonoids without OH or only two OH groups on their benzene rings, purpurin with three OH groups, two of which are located in the ortho position of the anthraquinone molecule, exhibited the highest activity in antioxidative and anti-inflammatory cell assays. In addition, glycosides display lower activities than their aglycons [75].


Active ingredientsModels of ALIDoses (mg/kg)Relevant findingsRef.

EmodinALI in mice induced by LPS20Upregulate the expression of BECN1 and LC3-II[61]
ALI in rats induced by SAP10Decrease the expression of PBEF[62]
ALI in rats induced by CLP25Inhibit p38 MAPK pathway, and reduce oxidative stress and inflammation response[63]
ALI in mice induced by CS20 and 40Enhance the expressions and activities of HO-1 and Nrf-2[64]
ChrysophanolALI in mice induced by PQ10 and 20Activate PPAR-γ and inhibit NF-κB pathway[65]
Tanshinone IIAALI in mice induced by LPS10Modulate Sirt1/NF-κB pathway[66]
ALI in rats induced by PQ25Enhance the levels of ACE2 and Ang-(1-7)[67]
ALI in rats induced by seawater aspiration10Downregulate MIF and the activity of NF-κB[68]
CryptotanshinoneALI in mice induced by LPS10, 20, and 40Inhibit TLR4-mediated NF-κB pathways[69]
ALI in rats induced by radiation20Regulate the production and release of inflammatory cytokines especially MMP-1, and inhibit the activation of CCL3/CCR1[70]
EmbelinALI in rats induced by PQ20Suppress oxidative stress and inflammatory cascade by modulating MAPK/NF-κB pathway[71]
ShikoninALI in rats induced by LPS12.5, 25, and 50Regulate miRNA-140-5p/TLR4-a[72]
ALI in mice induced by LPS12.5 and 25Inhibit MD2-TLR4 complex formation[73]
AloinALI in mice induced by LPS1.6~12.4Reduce inflammatory gene iNOS by inhibition activity and p-STAT-1 and NF-κB[132]

2.6. Other Components

In addition to flavonoids, saponins, terpenoids, alkaloids, and quinonoids, other active ingredients, such as phenols, organic acids, coumarins, and lignans, also play important roles in ALI prevention and treatment (Table 6). The structures of other representative components are shown in Figure 6.


Active ingredientsModels of ALIDoses (mg/kg)Relevant findingsRef.

ResveratrolALI in murine induced by LPS30Activate SOCS3 pathway[76]
ALI in mice induced by CLP40Activate the VEGF-B pathway[77]
ALI in mice induced by SEB100Downregulate miR-193a that targets TGF-β pathway[78]
CurcuminALI in mice induced by CLP20Enhance Treg cell differentiation and increase IL-10 production[79]
ALI in mice induced by BLM75Downregulate the expression of Ki 67 and EGFR[80]
Ellagic acidALI in mice induced by HCl10Downregulate the level of IL-6 and upregulate the level of IL-10[81]
Protocatechuic acidALI in mice induced by LPS5, 15, and 30Suppress p38MAPK and NF-κB pathways[82]
EugenolALI in mice induced by LPS150Suppress the release of inflammatory factors and the activity of antioxidant enzymes[83]
Veratric acidALI in mice induced by LPS12.5, 25, and 50Inhibit NF-κB pathway[84]
EsculinALI in mice induced by LPS20 and 40Inhibit TLR/NF-κB pathway[85]
ArctiinALI in mice induced by LPS10, 20, and 40Suppress PI3K/AKT/NF-κB pathway[86]
ArctigeninALI in mice induced by LPS50Suppress MAPK, HO-1, and iNOS pathway[87]

Resveratrol is a stilbene derivative mainly present in Vitis viniferae fructus. It exhibits protective effects in various ALI models. In a LPS-mediated ALI model, resveratrol can counteract lung inflammation by suppressing CD45+ Siglec F- and CD45+ CD206- M1 subtype macrophages [76]. In a sepsis-induced ALI model, resveratrol can suppress the production of proinflammatory cytokines and the apoptosis of alveolar macrophages through the activation of the vascular endothelial growth factor-B (VEGF-B) pathway, thereby exhibiting anti-inflammatory and antiapoptotic effects [77]. In a staphylococcal enterotoxin B- (SEB-) induced ALI model, resveratrol can ameliorate ALI and decrease mortality through miR-193a regulation that targets the TGF-β pathway [78].

Curcumin is a natural polyphenolic compound found in Curcuma longa. Curcumin pretreatment can relieve the severity of ALI and uncontrolled inflammation in CLP-induced septic mice by enhancing the differentiation of naïve CD4+ T cells into CD4+ CD25+ FOXP3+ Treg cells [79]. Moreover, curcumin can significantly improve BLM-induced ALI by downregulating the levels of epidermal growth factor receptor (EGFR) and Ki 67 both in vitro and in vivo [80].

Ellagic acid, a naturally occurring polyphenol, is present in a variety of plants such as eucalyptus, green tea, and geranium. In preventive and therapeutic treatments, ellagic acid can restrain the development of ALI induced by HCl by reducing IL-6 levels and increasing IL-10 levels in BALF [81].

Protocatechuic acid, a dihydroxybenzoic acid, is a phenolic acid found in plants such as Alpinia oxyphylla. It can effectively ameliorate lung histopathological changes induced by LPS by suppressing the p38 MAPK and NF-κB signaling pathways [82].

Eugenol is a natural phenolic substance found in medicinal plants, such as cinnamon, clove, and bay leaves. Eugenol can alleviate LPS-induced ALI by suppressing the release of inflammatory mediators (IL-1β, TNF-α, and IL-6), NADPH oxidase activity, and antioxidant enzyme activity [83].

Veratric acid is a benzoic acid extracted from Trollius chinensis Bunge. It can attenuate inflammatory injury caused by LPS by inhibiting NF-κB signaling pathways [84].

Esculin, a coumarin compound isolated from Fraxini cortex, can inhibit LPS-induced lung inflammation in mice by regulating the TLRs/MyD88/NF-κB signaling pathways [85].

Arctiin and arctigenin are lignan compounds isolated from Arctium lappa. Arctiin can prevent LPS-induced ALI in mice by inhibiting the PI3K/AKT/NF-κB signaling pathway [86], and arctigenin can provide protection against LPS-induced lung inflammation and oxidative stress in a mouse model by suppressing the MAPK, iNOS, and HO-1 pathway [87].

3. Discussion

By organizing the active ingredients from herbs and their roles in preventing and treating ALI, the mechanisms can be summarized as follows:

3.1. Improvement of Pathological Changes
3.1.1. Inhibition of the Inflammatory Response

Under ALI, neutrophils, macrophages, vascular endothelial cells, and many other immune cells are activated in the body to release a series of inflammatory mediators, leading to an uncontrolled systemic inflammatory response [1]. This activation is one of the important mechanisms of ALI prevention and control with herbal active ingredients, regulation of the levels of inflammatory mediators, and balancing of pro- and anti-inflammatory responses [70, 81].

3.1.2. Amelioration of the Barrier Function

The main pathological features of ALI include pulmonary edema caused by the destruction of the alveolar-capillary barrier and imbalance in the inflammatory response caused by leukocyte recruitment [2]. The destruction of alveolar epithelial cells increases barrier permeability and decreases the clearance rate of alveolar fluid; injury to vascular endothelial cells leads to fluid and macromolecules entering the gap, thus causing pulmonary edema. Herbal active ingredients, such as platycodin D and astragaloside IV, can maintain the integrity of the barrier function by inhibiting the apoptosis of alveolar epithelium or endothelial cells [32, 88].

3.1.3. Alleviation of Oxidative Stress

Under ALI, activated neutrophils release a large amount of ROS. The release of considerable ROS, on the one hand, directly damages the unsaturated fatty acids in the cell membrane, reduces the fluidity of the membrane, and increases permeability. On the other hand, it can release substantial oxygen-free radicals to lung tissue, which directly damages alveolar epithelial and pulmonary vascular endothelial cells, destroys the blood barrier, and aggravates pulmonary edema [89]. Therefore, reconstruction of the balance between oxidation and antioxidation can ease ALI. Studies have shown that herbal active ingredients, including tectorigenin and arctigenin, can ease oxidative stress and pathological damage to the lung by increasing the contents of SOD and HO-1 [7, 87].

3.2. Regulation of ALI-Related Pathways
3.2.1. Inhibition of the NF-κB Pathway

When the ALI occurs, the body will produce a large number of inflammatory factors. Their transcription is mainly related to NF-κB, a key nuclear transcription factor. In resting cells, NF-κB and IκB form a compound body that exists in the cytoplasm in an inactive form. When the cell is stimulated by extracellular signals, IκB phosphorylates and free NF-κB rapidly shift to the nucleus, thereby inducing the transcription of related genes, including proinflammatory factors IL-6 and TNF-α, and aggravating ALI [90]. Many researches demonstrated that some herbal active ingredients can improve ALI by inhibiting the NF-κB pathway [29, 50, 84].

3.2.2. Inhibition of the MAPK Pathway

MAPK activation is crucial in the occurrence and development of ALI. MAPK includes three main subfamilies, namely, ERK, JNK, and p38, which can regulate cytokine release and signal transduction in ALI. JNK and p38 can regulate the occurrence of proinflammatory factors IL-6 and TNF-α. p38 can regulate the activation of NF-κB induced by LPS by inhibiting neutrophil migration and aggravate the disease condition of ALI patients [91]. Hesperidin, emodin, and other herbal active ingredients can alleviate the development of ALI by inhibiting the MAPK pathway [12, 63].

3.2.3. Other Pathway

Herbal active ingredients can also affect the occurrence and development of ALI by regulating Akt, AMPK, cAMP/PKA, or TGF-β pathways [16, 40, 78, 92]. The anti-ALI mechanisms of herbal active ingredients are summarized in Figure 7.

3.3. Regulation of ALI-Related Receptors
3.3.1. Inhibition of TLRs

TLRs are important proteins involved in nonspecific immunity. TLR2 and TLR4 can recognize LPS and play an important role in LPS-mediated inflammatory responses. After invading the lung, LPS binds to the TLR2 or TLR4 receptor, which activates the NF-κB pathway and induces inflammation. Therefore, inhibition of TLR2 or TLR4 activation can ease immune and inflammatory responses [93]. Studies have shown that hydroxysafflor yellow A and ginsenoside Rb1 can alleviate ALI by inhibiting the expression of TLR4 or TLR2 [37, 94].

3.3.2. Upregulation of PPAR-γ

The imbalance in inflammatory response and immune regulation can promote the occurrence and development of ALI. Studies have revealed that activated PPAR-γ has anti-inflammatory and immunoregulation effects [95, 96]. Triptolide and citral can inhibit the activation of NF-κB by increasing the content of PPAR-γ, thus improving the inflammatory response of ALI [97, 98].

3.3.3. Activation of the Nuclear Receptor LXRα

LXRα, one of the main members of the nuclear receptor superfamily, can selectively reduce the expression of pulmonary inflammatory factors when activated and inhibit the activity of neutrophils and macrophages, which play a key role in the ALI inflammatory response. It can also increase the expression of several immune proteins and antioxidant enzymes in the lung. Therefore, LXRα is a potential anti-ALI target [99]. Researches have shown that acanthoic acid and platycodin D can alleviate lung inflammation by activating LXRα [31, 100].

4. Conclusion and Outlook

Herbal active ingredients for preventing and treating ALI mainly include flavonoids, terpenoids, saponins, alkaloids, and quinonoids, and animal models are used to verify their efficacy. The LPS-induced ALI model is the most widely used, and the main modeling methods include intraperitoneal injection, tracheal instillation, nasal instillation, and tail intravenous injection. The cecal ligation and puncture-induced in vivo sepsis model, retrograde pancreaticobiliary duct injection of taurocholic acid-induced severe acute pancreatitis model, tail intravenous injection of oleic acid, tracheal instillation of BLM, inhalation of influenza virus, and intraperitoneal injection of PQ are also to induce the ALI model. Although the verification of activity is simple at the cellular level, multicell interaction during ALI occurrence cannot be stimulated accurately. Most laboratories use Western blot and other methods to investigate changes in the protein contents of related pathways, but interference or knockout is rarely used in confirming the specificity of proteins and their related upstream and downstream proteins. The inhibitors of related pathways are also seldom used. Therefore, clarifying the possible targets of the active ingredients from herbs seems difficult.

In summary, herbal active ingredients possess anti-ALI activity and can ameliorate ALI by regulating immune cell function, inhibiting inflammatory response, improving barrier function, and modulating related signal transduction pathways. Further studies are needed to confirm the action target and possible structural modification and to provide insights and references for the discovery of novel drugs for ALI prevention and treatment.

Abbreviations

ALI:Acute lung injury
ABCA1:ATP-binding cassette transporter A1
AIM2:Absent in melanoma 2
ACE2:Angiotensin-converting enzyme 2
BALF:Bronchoalveolar lavage fluids
Bcl-2:B-cell lymphoma-2
Bax:Bcl2-associated X protein
BLM:Bleomycin
CAT:Catalase
COX-2:Cyclo-oxygen-ase-2
CLP:Cecal ligation and puncture
CS:Cigarette smoke
CCL3:CC chemokine ligand 3
CCR1:CC chemokine receptor 1
E. coli:Escherichia coli
EGCG:Epigallocatechin-3-gallate
ERK:Extracellular regulated kinases
ER:Endoplasmic reticulum
EGFR:Epidermal growth factor receptor
GSH-Px:Glutathione peroxidase
HKMRSA:Heat-killed methicillin-resistant Staphylococcus aureus
Hsp70:Heat shock protein 70
HO-1:Heme oxygenase-1
HMGB1:High mobility group box-1 protein
IR:Ischemia-reperfusion
IL:Interleukin
ICAM-1:Intercellular cell adhesion molecule-1
JNK:c-Jun N-terminal kinase
LPS:Lipopolysaccharides
LXRα:Liver x receptor α
MD2:Myeloid differentiation protein 2
MMP-9:Matrix metalloprotein-9
MPO:Myeloperoxidase
MyD88:Myeloid differential protein-88
MAPK:Mitogen-activated protein kinase
MDA:Malondialdehyde
NF-κB:Nuclear factor kappa b
Nrf2:Nuclear factor E2-related factor 2
NLRP3:Nod-like receptor pyrin domain-containing protein 3
OA:Oleic acid
OVA:Ovalbumin
PQ:Paraquat
PPAR-γ:Peroxisome proliferator-activated receptors-γ
ROS:Reactive oxygen species
SAP:Severe acute pancreatitis
SCI:Spinal cord injury
SEB:Staphylococcal enterotoxin B
SOD:Superoxide dismutase
TGF-β:Transforming growth factor-β
TNF-α:Tumor necrosis factor-α
TIMP-1:Tissue inhibitor of metalloproteinase-1
TLR4:Toll-like receptor 4
VEGF-B:Vascular endothelial growth factor-B.

Conflicts of Interest

The authors have no conflicts of interest to declare.

Acknowledgments

This work is financially supported by the Zhejiang Natural Science Foundation (No. LY19H280012), the National Natural Science Foundation of China (No. 81603368), the Health Commission of Zhejiang Province (No. 2021KY632), and the Zhejiang Provincial Department of Science and Technology (Nos. LGF21H280008 and YS2021015).

References

  1. V. Fanelli and V. M. Ranieri, “Mechanisms and clinical consequences of acute lung injury,” Annals of the American Thoracic Society, vol. 12, Supplement 1, pp. S3–S8, 2015. View at: Publisher Site | Google Scholar
  2. L. B. Ware, “Pathophysiology of acute lung injury and the acute respiratory distress syndrome,” Seminars in Respiratory and Critical Care Medicine, vol. 27, no. 4, pp. 337–349, 2006. View at: Publisher Site | Google Scholar
  3. R. M. Sweeney, M. Griffiths, and D. McAuley, “Treatment of acute lung injury: current and emerging pharmacological therapies,” Seminars in Respiratory and Critical Care Medicine, vol. 34, no. 4, pp. 487–498, 2013. View at: Publisher Site | Google Scholar
  4. A. N. Panche, A. D. Diwan, and S. R. Chandra, “Flavonoids: an overview,” Journal of Nutritional Science, vol. 5, 2016. View at: Publisher Site | Google Scholar
  5. Y. Chen, Y. C. Nie, Y. L. Luo et al., “Protective effects of naringin against paraquat-induced acute lung injury and pulmonary fibrosis in mice,” Food and Chemical Toxicology, vol. 58, pp. 133–140, 2013. View at: Publisher Site | Google Scholar
  6. Y. Chen, H. Wu, Y. C. Nie, P. B. Li, J. G. Shen, and W. W. Su, “Mucoactive effects of naringin in lipopolysaccharide-induced acute lung injury mice and beagle dogs,” Environmental Toxicology and Pharmacology, vol. 38, no. 1, pp. 279–287, 2014. View at: Publisher Site | Google Scholar
  7. C. H. Ma, J. P. Liu, R. Qu, and S. P. Ma, “Tectorigenin inhibits the inflammation of LPS-induced acute lung injury in mice,” Chinese Journal of Natural Medicines, vol. 12, no. 11, pp. 841–846, 2014. View at: Publisher Site | Google Scholar
  8. X. Meng, L. Hu, and W. Li, “Baicalin ameliorates lipopolysaccharide-induced acute lung injury in mice by suppressing oxidative stress and inflammation via the activation of the Nrf2-mediated HO-1 signaling pathway,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 392, no. 11, pp. 1421–1433, 2019. View at: Publisher Site | Google Scholar
  9. C. Bai, T. Li, Q. Sun et al., “Protective effect of baicalin against severe burn induced remote acute lung injury in rats,” Molecular Medicine Reports, vol. 17, no. 2, pp. 2689–2694, 2018. View at: Publisher Site | Google Scholar
  10. L. Y. Peng, M. Yuan, K. Song et al., “Baicalin alleviated APEC-induced acute lung injury in chicken by inhibiting NF-κB pathway activation,” International Immunopharmacology, vol. 72, pp. 467–472, 2019. View at: Publisher Site | Google Scholar
  11. X. Yuan, J. Zhu, Q. Kang, X. He, and D. Guo, “Protective effect of hesperidin against sepsis-induced lung injury by inducing the heat-stable protein 70 (Hsp70)/toll-like receptor 4 (TLR4)/ myeloid differentiation primary response 88 (MyD88) pathway,” Medical Science Monitor, vol. 25, pp. 107–114, 2019. View at: Publisher Site | Google Scholar
  12. Z. Ding, G. Sun, and Z. Zhu, “Hesperidin attenuates influenza A virus (H1N1) induced lung injury in rats through its anti-inflammatory effect,” Antiviral Therapy, vol. 23, no. 7, pp. 611–615, 2018. View at: Publisher Site | Google Scholar
  13. X. X. Liu, D. D. Yu, M. J. Chen et al., “Hesperidin ameliorates lipopolysaccharide-induced acute lung injury in mice by inhibiting HMGB1 release,” International Immunopharmacology, vol. 25, no. 2, pp. 370–376, 2015. View at: Publisher Site | Google Scholar
  14. Y. Liu, Z. Li, X. Xue, Y. Wang, Y. Zhang, and J. Wang, “Apigenin reverses lung injury and immunotoxicity in paraquat-treated mice,” International Immunopharmacology, vol. 65, pp. 531–538, 2018. View at: Publisher Site | Google Scholar
  15. J. Wang, Y. T. Liu, L. Xiao, L. Zhu, Q. Wang, and T. Yan, “Anti-inflammatory effects of apigenin in lipopolysaccharide-induced inflammatory in acute lung injury by suppressing COX-2 and NF-kB pathway,” Inflammation, vol. 37, no. 6, pp. 2085–2090, 2014. View at: Publisher Site | Google Scholar
  16. Q. Liu, H. Lv, Z. Wen, X. Ci, and L. Peng, “Isoliquiritigenin activates nuclear factor erythroid-2 related factor 2 to suppress the NOD-like receptor protein 3 inflammasome and inhibits the NF-κB pathway in macrophages and in acute lung injury,” Frontiers in Immunology, vol. 8, p. 1518, 2017. View at: Publisher Site | Google Scholar
  17. M. S. A. Khan, S. U. K. Khundmiri, S. R. Khundmiri, M. M. Al-Sanea, and P. L. Mok, “Fruit-derived polysaccharides and terpenoids: recent update on the gastroprotective Effects and mechanisms,” Frontiers in Pharmacology, vol. 9, p. 569, 2018. View at: Publisher Site | Google Scholar
  18. M. O. Germoush, H. A. Elgebaly, S. Hassan, E. M. Kamel, M. Bin-Jumah, and A. M. Mahmoud, “Consumption of terpenoids-rich padina pavonia extract attenuates hyperglycemia, insulin resistance and oxidative stress, and upregulates PPARγ in a rat model of type 2 diabetes,” Antioxidants, vol. 9, no. 1, p. 22, 2020. View at: Publisher Site | Google Scholar
  19. S. Peng, J. Gao, W. Liu et al., “Andrographolide ameliorates OVA-induced lung injury in mice by suppressing ROS-mediated NF-κB signaling and NLRP3 inflammasome activation,” Oncotarget, vol. 7, no. 49, pp. 80262–80274, 2016. View at: Publisher Site | Google Scholar
  20. J. Gao, S. Peng, X. Shan et al., “Inhibition of AIM2 inflammasome-mediated pyroptosis by andrographolide contributes to amelioration of radiation-induced lung inflammation and fibrosis,” Cell Death & Disease, vol. 10, no. 12, p. 957, 2019. View at: Publisher Site | Google Scholar
  21. S. P. Guan, W. Tee, D. S. Ng et al., “Andrographolide protects against cigarette smoke-induced oxidative lung injury via augmentation of Nrf2 activity,” British Journal of Pharmacology, vol. 168, no. 7, pp. 1707–1718, 2013. View at: Publisher Site | Google Scholar
  22. H. Yang, H. Lv, H. Li, X. Ci, and L. Peng, “Oridonin protects LPS-induced acute lung injury by modulating Nrf2-mediated oxidative stress and Nrf2-independent NLRP3 and NF-κB pathways,” Cell Communication and Signaling: CCS, vol. 17, no. 1, p. 62, 2019. View at: Publisher Site | Google Scholar
  23. Y. Liu, P. X. Zhang, C. H. Han et al., “Oridonin protects the lung against hyperoxia-induced injury in a mouse model,” Undersea & Hyperbaric Medicine, vol. 44, no. 1, pp. 33–38, 2017. View at: Publisher Site | Google Scholar
  24. H. Zhao, Z. Liu, W. Liu, X. Han, and M. Zhao, “Betulin attenuates lung and liver injuries in sepsis,” International Immunopharmacology, vol. 30, pp. 50–56, 2016. View at: Publisher Site | Google Scholar
  25. M. C. Lingaraju, N. N. Pathak, J. Begum et al., “Betulinic acid negates oxidative lung injury in surgical sepsis model,” The Journal of Surgical Research, vol. 193, no. 2, pp. 856–867, 2015. View at: Publisher Site | Google Scholar
  26. Z. Li, X. Xiao, and M. Yang, “Asiatic acid inhibits lipopolysaccharide-induced acute lung injury in mice,” Inflammation, vol. 39, no. 5, pp. 1642–1648, 2016. View at: Publisher Site | Google Scholar
  27. H. M. Li, M. Fan, Y. Xue et al., “Guaiane-type sesquiterpenoids from alismatis rhizoma and their anti-inflammatory activity,” Chemical and Pharmaceutical Bulletin, vol. 65, no. 4, pp. 403–407, 2017. View at: Publisher Site | Google Scholar
  28. M.-A. Lacaille-Dubois and M. Melzig, “Saponins: current progress and perspectives,” Planta Medica, vol. 82, no. 18, p. 1495, 2016. View at: Publisher Site | Google Scholar
  29. J. Qiu, L. Yu, X. Zhang et al., “Asiaticoside attenuates lipopolysaccharide-induced acute lung injury via down- regulation of NF-κB signaling pathway,” International Immunopharmacology, vol. 26, no. 1, pp. 181–187, 2015. View at: Publisher Site | Google Scholar
  30. L. N. Zhang, J. J. Zheng, L. Zhang et al., “Protective effects of asiaticoside on septic lung injury in mice,” Experimental and Toxicologic Pathology, vol. 63, no. 6, pp. 519–525, 2011. View at: Publisher Site | Google Scholar
  31. X. Hu, Y. Fu, X. Lu et al., “Protective effects of platycodin D on lipopolysaccharide-induced acute lung injury by activating LXRα-ABCA1 signaling pathway,” Frontiers in Immunology, vol. 7, 2017. View at: Publisher Site | Google Scholar
  32. W. Tao, Q. Su, H. Wang et al., “Platycodin D attenuates acute lung injury by suppressing apoptosis and inflammation in vivo and in vitro,” International Immunopharmacology, vol. 27, no. 1, pp. 138–147, 2015. View at: Publisher Site | Google Scholar
  33. C. Wang, Q. Li, and T. Li, “Dioscin alleviates lipopolysaccharide-induced acute lung injury through suppression of TLR4 signaling pathways,” Experimental Lung Research, vol. 46, no. 1-2, pp. 11–22, 2020. View at: Publisher Site | Google Scholar
  34. X. Yu, N. Zhang, W. Lin et al., “Regulatory effects of four ginsenoside monomers in humoral immunity of systemic lupus erythematosus,” Experimental and Therapeutic Medicine, vol. 15, no. 2, pp. 2097–2103, 2018. View at: Publisher Site | Google Scholar
  35. Y. Zhou, Y. P. Wang, Y. H. He, and J. C. Ding, “Ginsenoside Rg1 performs anti-aging functions by suppressing mitochondrial pathway-mediated apoptosis and activating sirtuin 3 (SIRT3)/superoxide dismutase 2 (SOD2) pathway in Sca-1+ HSC/HPC cells of an aging rat model,” Medical Science Monitor, vol. 26, 2020. View at: Publisher Site | Google Scholar
  36. X. Lyu, X. Xu, A. Song, J. Guo, Y. Zhang, and Y. Zhang, “Ginsenoside Rh1 inhibits colorectal cancer cell migration and invasion in vitro and tumor growth in vivo,” Oncology Letters, vol. 18, no. 4, pp. 4160–4166, 2019. View at: Publisher Site | Google Scholar
  37. A. Shaukat, Y. F. Guo, K. Jiang et al., “Ginsenoside Rb1 ameliorates Staphylococcus aureus-induced acute lung injury through attenuating NF-κB and MAPK activation,” Microbial Pathogenesis, vol. 132, pp. 302–312, 2019. View at: Publisher Site | Google Scholar
  38. Q.-L. Wang, L. Yang, Y. Peng et al., “Ginsenoside Rg1 regulates SIRT1 to ameliorate sepsis-induced lung inflammation and injury via inhibiting endoplasmic reticulum stress and inflammation,” Mediators of Inflammation, vol. 2019, Article ID 6453296, 10 pages, 2019. View at: Publisher Site | Google Scholar
  39. Y. Ye, Y. Shan, C. Bao, Y. Hu, and L. Wang, “Ginsenoside Rg1 protects against hind-limb ischemia reperfusion induced lung injury via NF-κB/COX-2 signaling pathway,” International Immunopharmacology, vol. 60, pp. 96–103, 2018. View at: Publisher Site | Google Scholar
  40. J. Yang, S. Li, L. Wang et al., “Ginsenoside Rg3 attenuates lipopolysaccharide-induced acute lung injury via MerTK-dependent activation of the PI3K/AKT/mTOR pathway,” Frontiers in Pharmacology, vol. 9, p. 850, 2018. View at: Publisher Site | Google Scholar
  41. J. Wang, X. F. Yu, J. J. Zhao, S. M. Shi, L. Fu, and D. Y. Sui, “Ginsenoside Rg3 attenuated omethoate-induced lung injury in rats,” Human & Experimental Toxicology, vol. 35, no. 6, pp. 677–684, 2016. View at: Publisher Site | Google Scholar
  42. Y.-H. Hsieh, J.-S. Deng, C. Yuan-Shiun, and G.-J. Huang, “Ginsenoside Rh2 ameliorates lipopolysaccharide-induced acute lung injury by regulating the TLR4/PI3K/Akt/mTOR, Raf-1/MEK/ERK, and Keap1/Nrf2/HO-1 signaling pathways in mice,” Nutrients, vol. 10, 2018. View at: Publisher Site | Google Scholar
  43. L. Zheng, Q. Zhu, C. Xu et al., “Glycyrrhizin mitigates radiation-induced acute lung injury by inhibiting the HMGB1/TLR4 signalling pathway,” Journal of Cellular and Molecular Medicine, vol. 24, no. 1, pp. 214–226, 2020. View at: Publisher Site | Google Scholar
  44. S. A. Lee, S. H. Lee, J. Y. Kim, and W. S. Lee, “Effects of glycyrrhizin on lipopolysaccharide-induced acute lung injury in a mouse model,” Journal of Thoracic Disease, vol. 11, no. 4, pp. 1287–1302, 2019. View at: Publisher Site | Google Scholar
  45. L. Yao and T. Sun, “Glycyrrhizin administration ameliorates Streptococcus aureus- induced acute lung injury,” International Immunopharmacology, vol. 70, pp. 504–511, 2019. View at: Publisher Site | Google Scholar
  46. F. Sun, J. Ruan, W. Zhao et al., “New dammarane-type triterpenoid saponins from panax notoginseng leaves and their nitric oxide inhibitory activities,” Molecules, vol. 25, no. 1, 2020. View at: Publisher Site | Google Scholar
  47. K. Zou, Z. Li, Y. Zhang et al., “Advances in the study of berberine and its derivatives: a focus on anti-inflammatory and anti-tumor effects in the digestive system,” Acta Pharmacologica Sinica, vol. 38, pp. 157–167, 2016. View at: Publisher Site | Google Scholar
  48. Y. Liu, Y. Xu, W. Ji et al., “Anti-tumor activities of matrine and oxymatrine: literature review,” Tumor Biology, vol. 35, no. 6, pp. 5111–5119, 2014. View at: Publisher Site | Google Scholar
  49. Y. Liang, C. Fan, X. Yan et al., “Berberine ameliorates lipopolysaccharide-induced acute lung injury via the PERK-mediated Nrf2/HO-1 signaling axis,” Phytotherapy Research, vol. 33, no. 1, pp. 130–148, 2019. View at: Publisher Site | Google Scholar
  50. K. Lin, S. Liu, Y. Shen, and Q. Li, “Berberine attenuates cigarette smoke-induced acute lung inflammation,” Inflammation, vol. 36, no. 5, pp. 1079–1086, 2013. View at: Publisher Site | Google Scholar
  51. S. Liu, Q. Chen, J. Liu, X. Yang, Y. Zhang, and F. Huang, “Sinomenine protects against _E.coli_ -induced acute lung injury in mice through Nrf2-NF-κB pathway,” Biomedicine & Pharmacotherapy, vol. 107, pp. 696–702, 2018. View at: Publisher Site | Google Scholar
  52. W. Wang, X. Yang, Q. Chen et al., “Sinomenine attenuates septic-associated lung injury through the Nrf2-Keap1 and autophagy,” The Journal of Pharmacy and Pharmacology, vol. 72, no. 2, pp. 259–270, 2020. View at: Publisher Site | Google Scholar
  53. C.-J. Liou, Y.-R. Lai, Y.-L. Chen, Y.-H. Chang, Z.-Y. Li, and W.-C. Huang, “Matrine attenuates COX-2 and ICAM-1 expressions in human lung epithelial cells and prevents acute lung injury in LPS-induced mice,” Mediators of Inflammation, vol. 2016, Article ID 3630485, 12 pages, 2016. View at: Publisher Site | Google Scholar
  54. Y. Wu, Y. Nie, J. Huang et al., “Protostemonine alleviates heat-killed methicillin-resistant Staphylococcus aureus-induced acute lung injury through MAPK and NF-κB signaling pathways,” International Immunopharmacology, vol. 77, p. 105964, 2019. View at: Publisher Site | Google Scholar
  55. Y. X. Wu, H. Q. He, Y. J. Nie, Y. H. Ding, L. Sun, and F. Qian, “Protostemonine effectively attenuates lipopolysaccharide-induced acute lung injury in mice,” Acta Pharmacologica Sinica, vol. 39, no. 1, pp. 85–96, 2018. View at: Publisher Site | Google Scholar
  56. J. Han, D. Ma, M. Zhang, X. Yang, and D. Tan, “Natural antioxidant betanin protects rats from paraquat-induced acute lung injury interstitial pneumonia,” BioMed Research International, vol. 2015, Article ID 608174, 9 pages, 2015. View at: Publisher Site | Google Scholar
  57. J. J. Chen, Y. L. Chang, C. M. Teng, and I. S. Chen, “Vasorelaxing and antioxidant constituents from Hernandia nymphaeifolia,” Planta Medica, vol. 67, no. 7, pp. 593–598, 2001. View at: Publisher Site | Google Scholar
  58. B. Borcsa, U. Widowitz, D. Csupor, P. Forgo, R. Bauer, and J. Hohmann, “Semisynthesis and pharmacological investigation of lipo-alkaloids prepared from aconitine,” Fitoterapia, vol. 82, no. 3, pp. 365–368, 2011. View at: Publisher Site | Google Scholar
  59. X. Dong, J. Fu, X. Yin et al., “Emodin: a review of its pharmacology, toxicity and pharmacokinetics,” Phytotherapy Research, vol. 30, no. 8, pp. 1207–1218, 2016. View at: Publisher Site | Google Scholar
  60. Y. M. A. Prateeksha, M. A. Yusuf, B. N. Singh et al., “Chrysophanol: a natural anthraquinone with multifaceted biotherapeutic potential,” Biomolecules, vol. 9, no. 2, p. 68, 2019. View at: Publisher Site | Google Scholar
  61. Y. Dong, L. Zhang, Y. Jiang, J. Dai, L. Tang, and G. Liu, “Emodin reactivated autophagy and alleviated inflammatory lung injury in mice with lethal endotoxemia,” Experimental Animals, vol. 68, no. 4, pp. 559–568, 2019. View at: Publisher Site | Google Scholar
  62. H. Cui, S. Li, C. Xu, J. Zhang, Z. Sun, and H. Chen, “Emodin alleviates severe acute pancreatitis-associated acute lung injury by decreasing pre-B-cell colony-enhancing factor expression and promoting polymorphonuclear neutrophil apoptosis,” Molecular Medicine Reports, vol. 16, no. 4, pp. 5121–5128, 2017. View at: Publisher Site | Google Scholar
  63. J. T. Yin, B. Wan, D. D. Liu et al., “Emodin alleviates lung injury in rats with sepsis,” The Journal of Surgical Research, vol. 202, no. 2, pp. 308–314, 2016. View at: Publisher Site | Google Scholar
  64. W. H. Xue, X. Q. Shi, S. H. Liang, L. Zhou, K. F. Liu, and J. Zhao, “Emodin attenuates cigarette smoke induced lung injury in a mouse model via suppression of reactive oxygen species production,” Journal of Biochemical and Molecular Toxicology, vol. 29, no. 11, pp. 526–532, 2015. View at: Publisher Site | Google Scholar
  65. A. Li, Y. Liu, L. Zhai, L. Wang, Z. Lin, and S. Wang, “Activating peroxisome proliferator-activated receptors (PPARs): a new sight for chrysophanol to treat paraquat-induced lung injury,” Inflammation, vol. 39, no. 2, pp. 928–937, 2016. View at: Publisher Site | Google Scholar
  66. M. Quan, Y. Lv, Y. Dai et al., “Tanshinone IIA protects against lipopolysaccharide-induced lung injury through targeting Sirt1,” The Journal of Pharmacy and Pharmacology, vol. 71, no. 7, pp. 1142–1151, 2019. View at: Publisher Site | Google Scholar
  67. Y. Wang, H. Wu, W. Niu et al., “Tanshinone IIA attenuates paraquat-induced acute lung injury by modulating angiotensin-converting enzyme 2/angiotensin‑(1‑7) in rats,” Molecular Medicine Reports, vol. 18, no. 3, pp. 2955–2962, 2018. View at: Publisher Site | Google Scholar
  68. Y. Zhang, B. Zhang, D. Q. Xu et al., “Tanshinone IIA attenuates seawater aspiration-induced lung injury by inhibiting macrophage migration inhibitory factor,” Biological & Pharmaceutical Bulletin, vol. 34, no. 7, pp. 1052–1057, 2011. View at: Publisher Site | Google Scholar
  69. Y. Tang, Y. Chen, Z. Chu, B. Yan, and L. Xu, “Protective effect of cryptotanshinone on lipopolysaccharide-induced acute lung injury in mice,” European Journal of Pharmacology, vol. 723, pp. 494–500, 2014. View at: Publisher Site | Google Scholar
  70. Y. Jiang, F. You, J. Zhu, C. Zheng, R. Yan, and J. Zeng, “Cryptotanshinone ameliorates radiation-induced lung injury in rats,” Evidence-based Complementary and Alternative Medicine, vol. 2019, Article ID 1908416, 14 pages, 2019. View at: Publisher Site | Google Scholar
  71. N. SreeHarsha, “Embelin impact on paraquat-induced lung injury through suppressing oxidative stress, inflammatory cascade, and MAPK/NF-κB signaling pathway,” Journal of Biochemical and Molecular Toxicology, vol. 34, no. 4, 2020. View at: Publisher Site | Google Scholar
  72. Y. Y. Zhang, X. Liu, X. Zhang, and J. Zhang, “Shikonin improve sepsis-induced lung injury via regulation of miRNA-140-5p/TLR4-a vitro and vivo study,” Journal of Cellular Biochemistry, vol. 121, no. 3, pp. 2103–2117, 2020. View at: Publisher Site | Google Scholar
  73. Y. Zhang, T. Xu, Z. Pan et al., “Shikonin inhibits myeloid differentiation protein 2 to prevent LPS-induced acute lung injury,” British Journal of Pharmacology, vol. 175, no. 5, pp. 840–854, 2018. View at: Publisher Site | Google Scholar
  74. W. Nam, S. P. Kim, S. H. Nam, and M. Friedman, “Structure-antioxidative and anti-inflammatory activity relationships of purpurin and related anthraquinones in chemical and cell assays,” Molecules, vol. 22, no. 2, p. 265, 2017. View at: Publisher Site | Google Scholar
  75. K. Xu, P. Wang, L. Wang et al., “Quinone derivatives from the genus Rubia and their bioactivities,” Chemistry & Biodiversity, vol. 11, no. 3, pp. 341–363, 2014. View at: Publisher Site | Google Scholar
  76. L. Hu, Z. Chen, L. Li, Z. Jiang, and L. Zhu, “Resveratrol decreases CD45+CD206-subtype macrophages in LPS-induced murine acute lung injury by SOCS3 signalling pathway,” Journal of Cellular and Molecular Medicine, vol. 23, no. 12, pp. 8101–8113, 2019. View at: Publisher Site | Google Scholar
  77. L. Yang, Z. Zhang, Y. Zhuo et al., “Resveratrol alleviates sepsis-induced acute lung injury by suppressing inflammation and apoptosis of alveolar macrophage cells,” American Journal of Translational Research, vol. 10, no. 7, pp. 1961–1975, 2018. View at: Google Scholar
  78. H. Alghetaa, A. Mohammed, M. Sultan et al., “Resveratrol protects mice against SEB-induced acute lung injury and mortality by miR-193a modulation that targets TGF-β signalling,” Journal of Cellular and Molecular Medicine, vol. 22, no. 5, pp. 2644–2655, 2018. View at: Publisher Site | Google Scholar
  79. Y. S. Chai, Y. Q. Chen, S. H. Lin et al., “Curcumin regulates the differentiation of naive CD4+T cells and activates IL-10 immune modulation against acute lung injury in mice,” Biomedicine & Pharmacotherapy, vol. 125, p. 109946, 2020. View at: Publisher Site | Google Scholar
  80. S. B. Shaikh, A. Prabhu, and Y. P. Bhandary, “Curcumin suppresses epithelial growth factor receptor (EGFR) and proliferative protein (Ki 67) in acute lung injury and lung fibrosis in vitro and in vivo,” Endocrine, Metabolic & Immune Disorders Drug Targets, vol. 20, no. 4, pp. 558–563, 2020. View at: Publisher Site | Google Scholar
  81. D. C. Favarin, M. M. Teixeira, E. L. de Andrade et al., “Anti-inflammatory effects of ellagic acid on acute lung injury induced by acid in mice,” Mediators of Inflammation, vol. 2013, Article ID 164202, 13 pages, 2013. View at: Publisher Site | Google Scholar
  82. X. Zhang, C. Li, J. Li, Y. Xu, S. Guan, and M. Zhao, “Protective effects of protocatechuic acid on acute lung injury induced by lipopolysaccharide in mice via p38MAPK and NF-κB signal pathways,” International Immunopharmacology, vol. 26, no. 1, pp. 229–236, 2015. View at: Publisher Site | Google Scholar
  83. C. B. Magalhães, N. V. Casquilho, M. N. Machado et al., “The anti-inflammatory and anti-oxidative actions of eugenol improve lipopolysaccharide-induced lung injury,” Respiratory Physiology & Neurobiology, vol. 259, pp. 30–36, 2019. View at: Publisher Site | Google Scholar
  84. X. Ran, S. Chao, Z. Jun-Gang, H. Yun, C. Kuan-Bing, and S. Wen-Jun, “Protective effect of veratric acid on lipopolysaccharide-induced acute lung injury in mice,” European Journal of Pharmacology, vol. 740, pp. 227–232, 2014. View at: Publisher Site | Google Scholar
  85. Z. Tianzhu and W. Shumin, “Esculin inhibits the inflammation of LPS-induced acute lung injury in mice via regulation of TLR/NF-κB pathways,” Inflammation, vol. 38, no. 4, pp. 1529–1536, 2015. View at: Publisher Site | Google Scholar
  86. B. Zhou, G. Weng, Z. Huang, T. Liu, and F. Dai, “Arctiin prevents LPS-induced acute lung injury via inhibition of PI3K/AKT signaling pathway in mice,” Inflammation, vol. 41, no. 6, pp. 2129–2135, 2018. View at: Publisher Site | Google Scholar
  87. W. Z. Zhang, Z. K. Jiang, B. X. He, and X. B. Liu, “Arctigenin protects against lipopolysaccharide-induced pulmonary oxidative stress and inflammation in a mouse model via suppression of MAPK, HO-1, and iNOS signaling,” Inflammation, vol. 38, no. 4, pp. 1406–1414, 2015. View at: Publisher Site | Google Scholar
  88. R. Huang and M. Li, “Protective effect of astragaloside IV against sepsis-induced acute lung injury in rats,” Saudi Pharmaceutical Journal, vol. 24, no. 3, pp. 341–347, 2016. View at: Publisher Site | Google Scholar
  89. M. Kellner, S. Noonepalle, Q. Lu, A. Srivastava, E. Zemskov, and S. M. Black, “ROS signaling in the pathogenesis of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS),” Advances in Experimental Medicine and Biology, vol. 967, pp. 105–137, 2017. View at: Publisher Site | Google Scholar
  90. X. Niu, F. Liu, W. Li et al., “Cavidine ameliorates lipopolysaccharide-induced acute lung injury via NF-κB signaling pathway in vivo and in vitro,” Inflammation, vol. 40, no. 4, pp. 1111–1122, 2017. View at: Publisher Site | Google Scholar
  91. X. Hu, H. Shen, Y. Wang, and M. Zhao, “Liver X Receptor Agonist TO901317 Attenuates Paraquat-Induced Acute Lung Injury through Inhibition of NF-κB and JNK/p38 MAPK Signal Pathways,” BioMed Research International, vol. 2017, Article ID 4652695, 13 pages, 2017. View at: Publisher Site | Google Scholar
  92. C. Wang, Q. Huang, C. Wang et al., “Hydroxysafflor yellow A suppress oleic acid-induced acute lung injury via protein kinase A,” Toxicology and Applied Pharmacology, vol. 272, no. 3, pp. 895–904, 2013. View at: Publisher Site | Google Scholar
  93. X. Ge, X. Meng, D. Fei, K. Kang, Q. Wang, and M. Zhao, “Lycorine attenuates lipopolysaccharide-induced acute lung injury through the HMGB1/TLRs/NF-κB pathway,” Biotech, vol. 10, no. 8, p. 369, 2020. View at: Publisher Site | Google Scholar
  94. Y. L. Liu, Y. J. Liu, Y. Liu et al., “Hydroxysafflor yellow A ameliorates lipopolysaccharide-induced acute lung injury in mice via modulating toll-like receptor 4 signaling pathways,” International Immunopharmacology, vol. 23, no. 2, pp. 649–657, 2014. View at: Publisher Site | Google Scholar
  95. W. Zhang, G. Wang, and S. Zhou, “Protective effects of isoliquiritigenin on LPS-induced acute lung injury by activating PPAR-γ,” Inflammation, vol. 41, no. 4, pp. 1290–1296, 2018. View at: Publisher Site | Google Scholar
  96. J. Ning, L. Xu, Q. Zhao, Y. Y. Zhang, and C. Q. Shen, “The protective effects of terpinen-4-ol on LPS-induced acute lung injury via activating PPAR-γ,” Inflammation, vol. 41, no. 6, pp. 2012–2017, 2018. View at: Publisher Site | Google Scholar
  97. D. Wei and Z. Huang, “Anti-inflammatory effects of triptolide in LPS-induced acute lung injury in mice,” Inflammation, vol. 37, no. 4, pp. 1307–1316, 2014. View at: Publisher Site | Google Scholar
  98. Y. Shen, Z. Sun, and X. Guo, “Citral inhibits lipopolysaccharide-induced acute lung injury by activating PPAR-γ,” European Journal of Pharmacology, vol. 747, pp. 45–51, 2015. View at: Publisher Site | Google Scholar
  99. K. Su, G. Zhang, X. Zhang, and W. Jiang, “Chikusetsusaponin V attenuates lipopolysaccharide-induced acute lung injury in mice by modulation of the NF-κB and LXRα,” International Immunopharmacology, vol. 70, pp. 174–179, 2019. View at: Publisher Site | Google Scholar
  100. W. Qiushi, L. Guanghua, and X. Guangquan, “Acanthoic acid ameliorates lipopolysaccharide-induced acute lung injury,” European Journal of Pharmacology, vol. 750, pp. 32–38, 2015. View at: Publisher Site | Google Scholar
  101. J. H. Lago, A. C. Toledo-Arruda, M. Mernak et al., “Structure-activity association of flavonoids in lung diseases,” Molecules, vol. 19, no. 3, pp. 3570–3595, 2014. View at: Publisher Site | Google Scholar
  102. Y. C. Huang, C. T. Horng, S. T. Chen et al., “Rutin improves endotoxin-induced acute lung injury via inhibition of iNOS and VCAM-1 expression,” Environmental Toxicology, vol. 31, no. 2, pp. 185–191, 2016. View at: Publisher Site | Google Scholar
  103. Y. Li, P. Ma, J. Fu, J. Wu, and X. Wu, “Combining an in silico approach with an animal experiment to investigate the protective effect of troxerutin for treating acute lung injury,” BMC Complementary and Alternative Medicine, vol. 19, no. 1, p. 124, 2019. View at: Publisher Site | Google Scholar
  104. Y. Wu, L. Wang, M. Jin, and B. X. Zang, “Hydroxysafflor yellow A alleviates early inflammatory response of bleomycin-induced mice lung injury,” Biological & Pharmaceutical Bulletin, vol. 35, no. 4, pp. 515–522, 2012. View at: Publisher Site | Google Scholar
  105. J. Wang, S. M. Fan, and J. Zhang, “Epigallocatechin-3-gallate ameliorates lipopolysaccharide-induced acute lung injury by suppression of TLR4/NF-κB signaling activation,” Brazilian Journal of Medical and Biological Research, vol. 52, no. 7, 2019. View at: Publisher Site | Google Scholar
  106. H. Shen, N. Wu, Z. Liu, H. Zhao, and M. Zhao, “Epigallocatechin-3-gallate alleviates paraquat-induced acute lung injury and inhibits upregulation of toll-like receptors,” Life Sciences, vol. 170, pp. 25–32, 2017. View at: Publisher Site | Google Scholar
  107. M. J. Xu, B. J. Liu, C. L. Wang et al., “Epigallocatechin-3-gallate inhibits TLR4 signaling through the 67-kDa laminin receptor and effectively alleviates acute lung injury induced by H9N2 swine influenza virus,” International Immunopharmacology, vol. 52, pp. 24–33, 2017. View at: Publisher Site | Google Scholar
  108. J. Qian, X. Chen, X. Chen et al., “Kaempferol reduces K63-linked polyubiquitination to inhibit nuclear factor-κB and inflammatory responses in acute lung injury in mice,” Toxicology Letters, vol. 306, pp. 53–60, 2019. View at: Publisher Site | Google Scholar
  109. D. J. Rabha, T. U. Singh, S. Rungsung et al., “Kaempferol attenuates acute lung injury in caecal ligation and puncture model of sepsis in mice,” Experimental Lung Research, vol. 44, no. 2, pp. 63–78, 2018. View at: Publisher Site | Google Scholar
  110. R. Zhang, X. Ai, Y. Duan et al., “Kaempferol ameliorates H9N2 swine influenza virus-induced acute lung injury by inactivation of TLR4/MyD88-mediated NF-κB and MAPK signaling pathways,” Biomedicine & Pharmacotherapy, vol. 89, pp. 660–672, 2017. View at: Publisher Site | Google Scholar
  111. E. J. Park, Y. M. Kim, H. J. Kim, and K. C. Chang, “Luteolin activates ERK1/2- and Ca2+-dependent HO-1 induction that reduces LPS-induced HMGB1, iNOS/NO, and COX-2 expression in RAW264.7 cells and mitigates acute lung injury of endotoxin mice,” Inflammation Research, vol. 67, no. 5, pp. 445–453, 2018. View at: Publisher Site | Google Scholar
  112. B. Liu, H. Yu, R. Baiyun et al., “Protective effects of dietary luteolin against mercuric chloride-induced lung injury in mice: involvement of AKT/Nrf2 and NF-κB pathways,” Food and Chemical Toxicology, vol. 113, pp. 296–302, 2018. View at: Publisher Site | Google Scholar
  113. X. F. Wang, S. D. Song, Y. J. Li et al., “Protective effect of quercetin in LPS-induced murine acute lung injury mediated by cAMP-Epac pathway,” Inflammation, vol. 41, no. 3, pp. 1093–1103, 2018. View at: Publisher Site | Google Scholar
  114. L. Meng, Z. Lv, Z. Z. Yu, D. Xu, and X. Yan, “Protective effect of quercetin on acute lung injury in rats with sepsis and its influence on ICAM-1 and MIP-2 expression,” Genetics and Molecular Research, vol. 15, no. 3, 2016. View at: Publisher Site | Google Scholar
  115. B. Wang and X. Mao, “Protective effect of quercetin against seawater instillation-induced acute lung injurythrough preventing M1 polarization of macrophages in mice,” Chinese Journal of Celluar and molecular immunology, vol. 33, pp. 751–755, 2017. View at: Google Scholar
  116. Y. C. Wang, Q. X. Liu, Q. Zheng et al., “Dihydromyricetin alleviates sepsis-induced acute lung injury through inhibiting NLRP3 inflammasome-dependent pyroptosis in mice model,” Inflammation, vol. 42, no. 4, pp. 1301–1310, 2019. View at: Publisher Site | Google Scholar
  117. W. Jiang, M. Li, F. He et al., “Protective effects of asiatic acid against spinal cord injury-induced acute lung injury in rats,” Inflammation, vol. 39, no. 6, pp. 1853–1861, 2016. View at: Publisher Site | Google Scholar
  118. Y. M. Wang, R. Ji, W. W. Chen et al., “Paclitaxel alleviated sepsis-induced acute lung injury by activating MUC1 and suppressing TLR-4/NF-κB pathway,” Drug Design, Development and Therapy, vol. Volume 13, pp. 3391–3404, 2019. View at: Publisher Site | Google Scholar
  119. K. Jiang, T. Zhang, N. Yin et al., “Geraniol alleviates LPS-induced acute lung injury in mice via inhibiting inflammation and apoptosis,” Oncotarget, vol. 8, no. 41, pp. 71038–71053, 2017. View at: Publisher Site | Google Scholar
  120. Y. Xiaofeng, C. Qinren, H. Jingping et al., “Geniposide, an iridoid glucoside derived fromGardenia jasminoides, protects against lipopolysaccharide-induced acute lung injury in mice,” Planta Medica, vol. 78, no. 6, pp. 557–564, 2012. View at: Publisher Site | Google Scholar
  121. H. Yang, Y. Li, P. Huo et al., “Protective effect of Jolkinolide B on LPS-induced mouse acute lung injury,” International Immunopharmacology, vol. 26, no. 1, pp. 119–124, 2015. View at: Publisher Site | Google Scholar
  122. Z. San, Y. Fu, W. Li et al., “Protective effect of taraxasterol on acute lung injury induced by lipopolysaccharide in mice,” International Immunopharmacology, vol. 19, no. 2, pp. 342–350, 2014. View at: Publisher Site | Google Scholar
  123. Z. L. Wu and J. Wang, “Dioscin attenuates bleomycin-induced acute lung injury via inhibiting the inflammatory response in mice,” Experimental Lung Research, vol. 45, no. 8, pp. 236–244, 2019. View at: Publisher Site | Google Scholar
  124. T. Chen, R. Wang, W. Jiang et al., “Protective effect of astragaloside IV against paraquat-induced lung injury in mice by suppressing Rho signaling,” Inflammation, vol. 39, no. 1, pp. 483–492, 2016. View at: Publisher Site | Google Scholar
  125. Z. A. Du, M. N. Sun, and Z. S. Hu, “Saikosaponin a ameliorates LPS-induced acute lung injury in mice,” Inflammation, vol. 41, no. 1, pp. 193–198, 2018. View at: Publisher Site | Google Scholar
  126. H. Lv, C. Zhu, Y. Liao et al., “Tenuigenin ameliorates acute lung injury by inhibiting NF-κB and MAPK signalling pathways,” Respiratory Physiology & Neurobiology, vol. 216, pp. 43–51, 2015. View at: Publisher Site | Google Scholar
  127. W.-t. Zhong, L.-x. Jiang, J.-y. Wei et al., “Protective effect of esculentoside A on lipopolysaccharide-induced acute lung injury in mice,” The Journal of Surgical Research, vol. 185, no. 1, pp. 364–372, 2013. View at: Publisher Site | Google Scholar
  128. D. Zhang, X. Li, Y. Hu et al., “Tabersonine attenuates lipopolysaccharide-induced acute lung injury via suppressing TRAF6 ubiquitination,” Biochemical Pharmacology, vol. 154, pp. 183–192, 2018. View at: Publisher Site | Google Scholar
  129. Q. H. You, D. Zhang, C. C. Niu et al., “Expression of IL-17A and IL-17F in lipopolysaccharide-induced acute lung injury and the counteraction of anisodamine or methylprednisolone,” Cytokine, vol. 66, no. 1, pp. 78–86, 2014. View at: Publisher Site | Google Scholar
  130. S. Guo, K. Jiang, H. Wu et al., “Magnoflorine ameliorates lipopolysaccharide-induced acute lung injury via suppressing NF-κB and MAPK activation,” Frontiers in Pharmacology, vol. 9, 2018. View at: Publisher Site | Google Scholar
  131. Y. Lu, D. Xu, J. Liu, and L. Gu, “Protective effect of sophocarpine on lipopolysaccharide-induced acute lung injury in mice,” International Immunopharmacology, vol. 70, pp. 180–186, 2019. View at: Publisher Site | Google Scholar
  132. W. Lee, S. Yang, C. Lee et al., “Aloin reduces inflammatory gene iNOS via inhibition activity and p-STAT-1 and NF-κB,” Food and Chemical Toxicology, vol. 126, pp. 67–71, 2019. View at: Publisher Site | Google Scholar

Copyright © 2021 Wen-Ying Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views263
Downloads708
Citations

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.